We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+11.56%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$8.44B
AUM Growth
+$1.09B
(+15%)
Cap. Flow
+$577M
Cap. Flow
% of AUM
6.84%
Top 10 Holdings %
Top 10 Hldgs %
15.63%
Holding
838
New
218
Increased
181
Reduced
162
Closed
220
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$123M |
| 2 |
HES
Hess
HES
|
+$115M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$108M |
| 4 |
Cencora
COR
|
+$106M |
| 5 |
Microsoft
MSFT
|
+$101M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$108M |
| 2 |
Analog Devices
ADI
|
+$105M |
| 3 |
Keysight
KEYS
|
+$101M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$82.2M |
| 5 |
Booking.com
BKNG
|
+$58.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.55% |
| 2 | Technology | 28% |
| 3 | Industrials | 9.43% |
| 4 | Energy | 7.74% |
| 5 | Consumer Discretionary | 5.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Syndax Pharmaceuticals
SNDX
$1.69B
| $12.8M | 0.15% |
+612,316
| New | +$12.7M |
|
177
Bristol-Myers Squibb
BMY
$133B
| $12.8M | 0.15% |
200,200
-61,413
| -23% | -$4.12M |
|
178
IDEX
IEX
$17B
| $12.6M | 0.15% |
+58,625
| New | +$12.3M |
|
179
Constellation Brands
STZ
$22.2B
| $12.6M | 0.15% |
+51,113
| New | +$12M |
|
180
Halozyme
HALO
$9.79B
| $12.5M | 0.15% |
+346,555
| New | +$11.8M |
|
181
Fox Class A
FOXA
$24.5B
| $12.4M | 0.15% |
363,928
+227,293
| +166% | +$7.44M |
|
182
Fortune Brands Innovations
FBIN
$5.88B
| $12.3M | 0.15% |
170,748
-21,976
| -11% | -$1.4M |
|
|
ITCI
183
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.2M | 0.14% |
+192,556
| New | +$12M |
|
184
Immunovant
IMVT
$7.93B
| $12M | 0.14% |
635,091
+497,499
| +362% | +$9.28M |
|
185
Protagonist Therapeutics
PTGX
$8.79B
| $11.8M | 0.14% |
427,264
-191,351
| -31% | -$4.79M |
|
186
Oscar Health
OSCR
$9.41B
| $11.8M | 0.14% |
1,463,616
+191,002
| +15% | +$1.41M |
|
187
Ross Stores
ROST
$80.5B
| $11.7M | 0.14% |
104,721
-16,360
| -14% | -$1.72M |
|
188
Jack in the Box
JACK
$312M
| $11.7M | 0.14% |
+120,094
| New | +$10.9M |
|
189
Legend Biotech
LEGN
$3.59B
| $11.7M | 0.14% |
169,305
+37,865
| +29% | +$2.47M |
|
190
Pultegroup
PHM
$24.1B
| $11.7M | 0.14% |
150,191
-109,078
| -42% | -$7.39M |
|
|
TXNM
191
TXNM Energy Inc
TXNM
$6.41B
| $11.3M | 0.13% |
250,056
-119,839
| -32% | -$5.64M |
|
192
Keros Therapeutics
KROS
$199M
| $11.2M | 0.13% |
279,701
+81,562
| +41% | +$3.58M |
|
193
Owens Corning
OC
$11.2B
| $11.2M | 0.13% |
86,020
+15,266
| +22% | +$1.67M |
|
194
Xenon Pharmaceuticals
XENE
$6.06B
| $11.2M | 0.13% |
290,400
-129,629
| -31% | -$5.15M |
|
|
AZPN
195
DELISTED
Aspen Technology Inc
AZPN
| $11.1M | 0.13% |
66,262
+38,577
| +139% | +$7.16M |
|
196
Ultragenyx Pharmaceutical
RARE
$2.45B
| $10.9M | 0.13% |
+236,564
| New | +$11M |
|
197
Workday
WDAY
$39.6B
| $10.9M | 0.13% |
48,225
+5,283
| +12% | +$1.06M |
|
198
Lennar Class A
LEN
$19.8B
| $10.9M | 0.13% |
+89,671
| New | +$9.79M |
|
|
KRTX
199
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $10.9M | 0.13% |
+50,100
| New | +$10.7M |
|
200
Roper Technologies
ROP
$38.8B
| $10.9M | 0.13% |
22,580
-26,200
| -54% | -$11.9M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Woodline Partners held 838 positions worth $8.44B, up 15% from $7.35B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Woodline Partners deployed $577M of net new capital in Q2 2023, opening 218 new positions and adding to 181 existing holdings. Its largest new stake was Hess: 837,083 shares worth $114M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Keysight, an estimated $101M trimmed.
- Woodline Partners's largest Q2 2023 buy was Hess: 837,083 shares worth $114M.
- Woodline Partners added most to Johnson & Johnson in Q2 2023, an estimated $123M increase.
- Woodline Partners's biggest Q2 2023 reduction was Keysight, cutting an estimated $101M.
- Woodline Partners fully exited Baxter International in Q2 2023, selling an estimated $108M.
- Woodline Partners's ten largest holdings make up 16% of its $8.44B portfolio in Q2 2023.
- Woodline Partners opened 218 new positions and closed 220 in Q2 2023.
- Woodline Partners's portfolio value rose 15% quarter-over-quarter to $8.44B.
Based on Woodline Partners's 13F filing for Q2 2023, filed 14 Aug 2023.